REQUEST A DEMO
Total
USD $0.00
Search more companies

Nexus Bioceuticals Sdn. Bhd. (Malaysia)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Nexus Bioceuticals Sdn. Bhd. Profile Updated: August 31, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Nexus Bioceuticals Sdn. Bhd. is an enterprise located in Malaysia, with the main office in Petaling Jaya. It operates in the Medicinal and Botanical Manufacturing sector. It was first established on September 26, 2017. There was a net sales revenue increase of 35.5% reported in Nexus Bioceuticals Sdn. Bhd.’s latest financial highlights for 2023. Its’ total assets recorded a negative growth of 9.24%. In 2023, Nexus Bioceuticals Sdn. Bhd.’s net profit margin increased by 10.41%.

Headquarters
Unit C-02-08 (Lobby 4),Block C, Damansara Intan,No.1, Jalan Ss 20/27,
Petaling Jaya; Selangor; Postal Code: 47400

Contact Details: Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.
Financial Auditors:
Purchase the Nexus Bioceuticals Sdn. Bhd. report to view the information.
Incorporation Date:
September 26, 2017
Key Executives
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Company Performance
Created with Highstock 1.3.7Chart context menu2020Y2021Y2022Y2023Y
Net sales revenue
Net Profit (Loss) for the Period
Net Profit Margin
Financial values in the chart are available after Nexus Bioceuticals Sdn. Bhd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency MYR. Absolute financial data is included in the purchased report.
Net sales revenue
35.5%
Total operating revenue
35.5%
Operating profit (EBIT)
611.79%
EBITDA
285.05%
Net Profit (Loss) for the Period
661.29%
Total assets
-9.24%
Total equity
100.06%
Operating Profit Margin (ROS)
13.47%
Net Profit Margin
10.41%
Return on Equity (ROE)
36.87%
Debt to Equity Ratio
-138.49%
Quick Ratio
0.29%
Cash Ratio
0.09%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?